Meeting report on the second targeted tumor therapies.

Abstract:

:This meeting report on the fourth Fabisch Symposium for Cancer Research and Molecular Biology describes the aims of the international meeting, the main topics of the presentations, and the highlights of the conference. The fourth Fabisch Symposium was the second on Targeted Tumor Therapies and held from April 1-3, 2009 in Berlin, Germany. The meeting focused on noncarrier-based targeted tumor therapies and their clinical application. The world's leading experts in this field presented the state of the art on tumor-specific targeting and tumor growth inhibition, drug design and production, and the description of innovative strategies for improved delivery. The topics concentrated on immunotoxins and other targeted toxins as anticancer drugs, thus providing a specialized meeting platform not existing elsewhere for these therapeutics. Although a number of innovative approaches on the avoidance of immune responses against highly effective toxins were presented, a notable conclusion of the meeting and direction for future research is the acute need to further reduce the immunogenicity of the targeted toxins, which hampers the efficacy of this group of therapeutics in clinical studies. The meeting successfully fostered plans for further research and cooperation between different groups to hopefully achieve advanced translational and clinical studies.

journal_name

Mol Cancer Ther

authors

Bachran C,Fuchs H

doi

10.1158/1535-7163.MCT-09-0491

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

17-23

issue

1

eissn

1535-7163

issn

1538-8514

pii

1535-7163.MCT-09-0491

journal_volume

9

pub_type

  • Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.

    abstract::During camptothecin- and etoposide (VP-16)-induced apoptosis in HL-60 cells, the expression level of cell death receptor-3 (DR3), cell death receptor-4 (DR4), and FAS remained mostly unchanged, whereas the expression of silencers of death domain (SODD) and FLICE inhibitory proteins, inhibitors of the cell death recept...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:

    authors: Bergeron S,Beauchemin M,Bertrand R

    更新日期:2004-12-01 00:00:00

  • The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma.

    abstract::Thalidomide is considered to be a potent antiangiogenic and immunomodulatory drug for cancer therapy. Earlier clinical studies have found that patients responding to this drug often had high plasma levels of basic fibroblast growth factor (bFGF). This cytokine is a proangiogenic factor overexpressed in many tumors and...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-07-2398

    authors: Mei SC,Wu RT

    更新日期:2008-08-01 00:00:00

  • Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.

    abstract::DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2-2.8 mg/kg; q3w) or weekly (0.8-1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase ...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1158/1535-7163.MCT-15-0693

    authors: Weekes CD,Lamberts LE,Borad MJ,Voortman J,McWilliams RR,Diamond JR,de Vries EG,Verheul HM,Lieu CH,Kim GP,Wang Y,Scales SJ,Samineni D,Brunstein F,Choi Y,Maslyar DJ,Colon-Otero G

    更新日期:2016-03-01 00:00:00

  • In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2.

    abstract::Antibodies conjugated to radionuclides emitting low-energy electrons, which include Auger electrons and some conversion electrons, were recently shown to efficiently kill cells bearing a high density of the antigen recognized. The primary purpose of this study was to determine if such killing could be obtained with an...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-04-0340

    authors: Michel RB,Andrews PM,Castillo ME,Mattes MJ

    更新日期:2005-06-01 00:00:00

  • Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

    abstract::Recombinant immunotoxins, consisting of single-chain variable fragments (scFv) genetically fused to polypeptide toxins, represent potentially effective candidates for cancer therapeutics. We evaluated the affinity of various anti-Her2/neu scFv fused to recombinant gelonin (rGel) and its effect on antitumor efficacy an...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-11-0519

    authors: Cao Y,Marks JD,Huang Q,Rudnick SI,Xiong C,Hittelman WN,Wen X,Marks JW,Cheung LH,Boland K,Li C,Adams GP,Rosenblum MG

    更新日期:2012-01-01 00:00:00

  • Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling.

    abstract::Radiotherapy, a frequent mode of cancer treatment, is often restricted by dose-related toxicity and development of therapeutic resistance. To develop a novel and selective radiosensitizer, we studied the radiosensitizing effects and associated mechanisms of silibinin in prostate cancer. The radiosensitizing effect of ...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-15-0348

    authors: Nambiar DK,Rajamani P,Deep G,Jain AK,Agarwal R,Singh RP

    更新日期:2015-12-01 00:00:00

  • Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.

    abstract::Advanced and hormone-refractory prostate cancer has long been considered as a chemoresistant disease. Recently, it was found that 14-3-3sigma expression increases as prostate tumor progresses, and that 14-3-3sigma contributes significantly to drug resistance in breast cancers. We, thus, hypothesized that advanced and ...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-05-0393

    authors: Han B,Xie H,Chen Q,Zhang JT

    更新日期:2006-04-01 00:00:00

  • Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.

    abstract::Viral and synthetic single-stranded RNAs are the ligands for Toll-like receptors 7 and 8 (TLR7 and TLR8). We have reported a novel class of synthetic oligoribonucleotides, referred to as stabilized immune-modulatory RNA compounds, which act as agonists of TLR7, TLR8, or both TLR7 and TLR8 depending on the sequence com...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-09-1198

    authors: Wang D,Precopio M,Lan T,Yu D,Tang JX,Kandimalla ER,Agrawal S

    更新日期:2010-06-01 00:00:00

  • Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.

    abstract::Long noncoding RNAs (lncRNA) have been found to play critical roles in tumorigenesis and the development of various cancers, including hepatocellular carcinoma (HCC). Metastasis associated with lung adenocarcinoma transcript-1 (MALAT1) has been identified as an oncogene and prognostic biomarker in HCC. Here, we demons...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-19-0203

    authors: Fan L,Huang X,Chen J,Zhang K,Gu YH,Sun J,Cui SY

    更新日期:2020-05-01 00:00:00

  • hKSR-2, a vitamin D-regulated gene, inhibits apoptosis in arabinocytosine-treated HL60 leukemia cells.

    abstract::Ras signaling can be modulated by the scaffolding activity of kinase suppressor of Ras-1 (KSR-1) and by the hKSR-2 protein, resulting in diverse phenotypic outcomes. The mitogen-activated protein kinase cascade downstream from Ras and KSRs includes Raf-1 and extracellular signal-regulated kinase 1/2 kinases, known to ...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-08-0276

    authors: Wang X,Patel R,Studzinski GP

    更新日期:2008-09-01 00:00:00

  • An optical probe for noninvasive molecular imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor.

    abstract::We have developed a near-infrared (NIR) probe that targets cells overexpressing the EGF receptor (EGFR) for imaging glioblastoma brain tumors in live subjects. A peptide specific for the EGFR was modified with various lengths of monodiscrete polyethylene glycol (PEG) units and a NIR Cy5.5 fluorescence dye. The lead co...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-12-0211

    authors: Agnes RS,Broome AM,Wang J,Verma A,Lavik K,Basilion JP

    更新日期:2012-10-01 00:00:00

  • Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.

    abstract::In breast and certain other cancers, receptor tyrosine kinases, including the insulin-like growth factor I receptor (IGF-IR), play an important role in promoting the oncogenic process. The IGF-IR is therefore an important target for developing new anti-breast cancer therapies. An initial screening of a chemical librar...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-05-0397

    authors: Gable KL,Maddux BA,Penaranda C,Zavodovskaya M,Campbell MJ,Lobo M,Robinson L,Schow S,Kerner JA,Goldfine ID,Youngren JF

    更新日期:2006-04-01 00:00:00

  • ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.

    abstract::Activin receptor-like kinase-1 (ALK1) is a type I, endothelial cell-specific member of the transforming growth factor-beta superfamily of receptors known to play an essential role in modulating angiogenesis and vessel maintenance. In the present study, we sought to examine the angiogenic and tumorigenic effects mediat...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-09-0650

    authors: Mitchell D,Pobre EG,Mulivor AW,Grinberg AV,Castonguay R,Monnell TE,Solban N,Ucran JA,Pearsall RS,Underwood KW,Seehra J,Kumar R

    更新日期:2010-02-01 00:00:00

  • Caspase-3-dependent mitotic checkpoint inactivation by the small-molecule inducers of mitotic slippage SU6656 and geraldol.

    abstract::Microtubule-targeting cancer drugs such as paclitaxel block cell-cycle progression at mitosis by prolonged activation of the mitotic checkpoint. Cells can spontaneously escape mitotic arrest and enter interphase without chromosome segregation by a process termed mitotic slippage that involves the degradation of cyclin...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-10-0909

    authors: Riffell JL,Jänicke RU,Roberge M

    更新日期:2011-05-01 00:00:00

  • Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR.

    abstract::Clinical circumvention of multidrug resistance (MDR) is a Sisyphian task faced in the treatment of many cancers. Identification of several mechanisms of acquired MDR has led to the development of chemosensitizing agents that counter specific mechanisms of MDR. Initial successes in therapy using "chemosensitizers" ofte...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Shain KH,Dalton WS

    更新日期:2001-11-01 00:00:00

  • Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.

    abstract::Hepatocellular carcinoma is highly chemoresistant, and ATP-binding cassette subfamily G member 2 (ABCG2) is thought to play a critical role in this drug resistance. The present study aims to develop effective therapeutic strategies to decrease ABCG2 expression level and to surmount drug resistance in hepatocellular ca...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-13-0201

    authors: Hou H,Sun H,Lu P,Ge C,Zhang L,Li H,Zhao F,Tian H,Zhang L,Chen T,Yao M,Li J

    更新日期:2013-12-01 00:00:00

  • Inhibition of tumor growth by a novel approach: in situ allicin generation using targeted alliinase delivery.

    abstract::Allicin (diallyl thiosulfinate), a highly active component in extracts of freshly crushed garlic, is the interaction product of non-protein amino acid alliin (S-allyl-L-cysteine sulfoxide) with the enzyme alliinase (alliin lyase; EC 4.4.1.4). Allicin was shown to be toxic in various mammalian cells in a dose-dependent...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:

    authors: Miron T,Mironchik M,Mirelman D,Wilchek M,Rabinkov A

    更新日期:2003-12-01 00:00:00

  • Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.

    abstract::Many malignant human tumors, including melanomas, are auxotrophic for arginine due to reduced expression of argininosuccinate synthetase-1 (ASS1), the rate-limiting enzyme for arginine biosynthesis. Pegylated arginine deiminase (ADI-PEG20), which degrades extracellular arginine, resulting in arginine deprivation, has ...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-13-0302

    authors: Long Y,Tsai WB,Wangpaichitr M,Tsukamoto T,Savaraj N,Feun LG,Kuo MT

    更新日期:2013-11-01 00:00:00

  • Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.

    abstract::The therapeutic efficiency of anticancer nucleoside analogues (NA) strongly depends on their intracellular accumulation and conversion into 5'-triphosphates. Because active NATP cannot be directly administrated due to instability, we present here a strategy of nanoencapsulation of these active drugs for efficient deli...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-08-0616

    authors: Galmarini CM,Warren G,Kohli E,Zeman A,Mitin A,Vinogradov SV

    更新日期:2008-10-01 00:00:00

  • TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity.

    abstract::We report the discovery, via a unique high-throughput screening strategy, of a novel bioactive anticancer compound: Thiol Alkylating Compound Inducing Massive Apoptosis (TACIMA)-218. We demonstrate that this molecule engenders apoptotic cell death in genetically diverse murine and human cancer cell lines, irrespective...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-20-0333

    authors: Abusarah J,Cui Y,El-Hachem N,El-Kadiry AE,Hammond-Martel I,Wurtele H,Beaudry A,Raynal NJ,Robert F,Pelletier J,Jankovic M,Mercier F,Kamyabiazar S,Annabi B,Rafei M

    更新日期:2021-01-01 00:00:00

  • Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo.

    abstract::Chemopreventive agents in colorectal cancer possess either antiproliferative or anti-inflammatory actions. Nonsteroidal anti-inflammatory drugs (NSAID) and cyclooxygenase-2 inhibitors have shown promise, but are compromised by side effects. Nitric oxide donor NSAIDs are organic nitrates conjugated via a labile linker ...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-07-0069

    authors: Hagos GK,Carroll RE,Kouznetsova T,Li Q,Toader V,Fernandez PA,Swanson SM,Thatcher GR

    更新日期:2007-08-01 00:00:00

  • Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.

    abstract::Small cell lung cancer (SCLC) has a poor prognosis. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase regulating cell proliferation, survival, migration, and invasion, which is overexpressed and/or activated in several cancers, including SCLC. We wanted to determine whether FAK contributes to SCLC aggressi...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-18-0328

    authors: Aboubakar Nana F,Lecocq M,Ladjemi MZ,Detry B,Dupasquier S,Feron O,Massion PP,Sibille Y,Pilette C,Ocak S

    更新日期:2019-01-01 00:00:00

  • The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.

    abstract::The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) is known to play a role in sensitivity to temozolomide. Promoter hypermethylation of MGMT is commonly used to predict low expression levels of MGMT in gliomas, despite observed discordance between promoter methylation and protein levels. Here, we i...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-13-0924

    authors: Moen EL,Stark AL,Zhang W,Dolan ME,Godley LA

    更新日期:2014-05-01 00:00:00

  • Novel peptide ligands for integrin alpha 4 beta 1 overexpressed in cancer cells.

    abstract::Using the "one-bead one-peptide" combinatorial technology, a library of random cyclic octapeptides and nonapeptides, consisting of natural and unnatural amino acids, was synthesized on polystyrene beads. This library was used to screen for peptides that promoted attachment and proliferation of bronchioloalveolar carci...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:

    authors: Mikawa M,Wang H,Guo L,Liu R,Marik J,Takada Y,Lam K,Lau D

    更新日期:2004-10-01 00:00:00

  • DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

    abstract::Antibody-drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S that targets CD22, an antigen with expression limited to B cells and the vast majority of non-Hodgkin lympho...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-12-1173

    authors: Li D,Poon KA,Yu SF,Dere R,Go M,Lau J,Zheng B,Elkins K,Danilenko D,Kozak KR,Chan P,Chuh J,Shi X,Nazzal D,Fuh F,McBride J,Ramakrishnan V,de Tute R,Rawstron A,Jack AS,Deng R,Chu YW,Dornan D,Williams M,Ho W,

    更新日期:2013-07-01 00:00:00

  • 2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation.

    abstract::Interference with endothelial cell metabolism is a promising, yet unexploited strategy for angiogenesis inhibition. We reported that the glucose analogue 2-deoxy-D-glucose (2-DG) inhibits angiogenesis at significantly lower concentrations than those required for tumor cytotoxicity. Here, we found that hypersensitivity...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-14-0315

    authors: Kovács K,Decatur C,Toro M,Pham DG,Liu H,Jing Y,Murray TG,Lampidis TJ,Merchan JR

    更新日期:2016-02-01 00:00:00

  • Targeted Inhibition of ULK1 Promotes Apoptosis and Suppresses Tumor Growth and Metastasis in Neuroblastoma.

    abstract::Neuroblastoma is the most common extracranial solid malignancy in the pediatric population, accounting for over 9% of all cancer-related deaths in children. Autophagy is a cell self-protective mechanism that promotes tumor cell growth and survival, making it an attractive target for treating cancer. However, the role ...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-18-0176

    authors: Dower CM,Bhat N,Gebru MT,Chen L,Wills CA,Miller BA,Wang HG

    更新日期:2018-11-01 00:00:00

  • Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

    abstract::Improved survival for patients with head and neck cancers (HNC) with recurrent and metastatic disease warrants that cancer therapy is specific, with protected delivery of the therapeutic agent to primary and metastatic cancer cells. A further objective should be that downregulation of the intracellular therapy target ...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-14-0166

    authors: Unger GM,Kren BT,Korman VL,Kimbrough TG,Vogel RI,Ondrey FG,Trembley JH,Ahmed K

    更新日期:2014-08-01 00:00:00

  • TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.

    abstract::Radiotherapy can be synergistically combined with immunotherapy in mouse models, extending its efficacious effects outside of the irradiated field (abscopal effects). We previously reported that a regimen encompassing local radiotherapy in combination with anti-CD137 plus anti-PD-1 mAbs achieves potent abscopal effect...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-18-0558

    authors: Rodríguez-Ruiz ME,Rodríguez I,Mayorga L,Labiano T,Barbes B,Etxeberria I,Ponz-Sarvise M,Azpilikueta A,Bolaños E,Sanmamed MF,Berraondo P,Calvo FA,Barcelos-Hoff MH,Perez-Gracia JL,Melero I

    更新日期:2019-03-01 00:00:00

  • An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities.

    abstract::Glycosylation is a complex multienzyme-related process that is frequently deregulated in cancer. Aberrant glycosylation can lead to the generation of novel tumor surface-specific glycotopes that can be targeted by antibodies. Murine DS6 mAb (muDS6) was generated from serous ovary adenocarcinoma immunization. It recogn...

    journal_title:Molecular cancer therapeutics

    pub_type: 杂志文章

    doi:10.1158/1535-7163.MCT-19-0826

    authors: Nicolazzi C,Caron A,Tellier A,Trombe M,Pinkas J,Payne G,Carrez C,Guérif S,Maguin M,Baffa R,Fassan M,Adam J,Mangatal-Wade L,Blanc V

    更新日期:2020-08-01 00:00:00